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Abstract The cannabinoid CB1 but not the CB2 receptor was
demonstrated to couple via GK16 to activate phospholipase C
after co-expression in COS7 cells. Chimeric CB1/CB2 receptors
were used as a model to study receptor^GK16 interaction. Se-
quences of the second and third intracellular loops and the car-
boxy-terminus were substituted from the CB1 into the CB2 re-
ceptor. Only the triple mutant with all three regions replaced
activated phospholipase C to a similar extent as the CB1 recep-
tor, suggesting that all three intracellular regions are required
for interacting with GK16. Several sub-domains within the third
intracellular loop were identi¢ed for receptor^GK16 interac-
tion. ) 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The G protein-coupled receptor represents one of the larg-
est protein families discovered in nature with over 1000 mem-
bers. They far outnumber the GK subunits identi¢ed so far.
Therefore, each GK subunit is able to couple to multiple re-
ceptors. Depending on their predominant signaling pathway,
most G protein-coupled receptors are referred to as GKs-,
GKi=o- or GKq-coupled. Among all the known GK subunits,
the human GK16 and its mouse homolog GK15 are unique
because they can couple a variety of GKs-, GKi=o- and GKq-
linked receptors to phospholipase C activation [1^5]. Because
of this promiscuous nature, GK16 has been referred to as a
universal G protein adapter with great implication for agonist
screening strategies, especially in the case of orphan receptors
[1].
Although GK15 and GK16 exhibit promiscuity towards G
protein-coupled receptors, they cannot be considered as uni-
versal adapters. We recently reported that the cannabinoid
CB1, but not the CB2 receptor, coupled to phospholipase C
activation to increase inositol phosphate formation after its
co-expression with GK16 in monkey kidney epithelial COS7
and human embryonic kidney HEK293 cells [6]. In addition
to the CB2 receptor, several G protein-coupled receptors also
did not interact with GK16, including the CCR2a chemokine
receptor [3], the K1A-adrenoceptor [7] and the MT1C melato-
nin receptor [5].
The molecular determinant for receptor^GK16 interaction is
still largely unknown. GK16 belongs to the GKq family (GK11,
GKq, GK14, GK15 and GK16) that couples to phospholipase C
activation [8]. Di¡erent sequences within the third intracellu-
lar (i3) loop of the K1B-adrenoceptor have been suggested to
be involved in coupling to GK16 and GKq=11 [9]. The present
study took advantage of the fact that the CB1 but not the CB2
receptor couples to GK16. Because of the high sequence ho-
mology between the two receptors and the ability of both to
interact with similar ligands, they can be used as a model
system for studying receptor^GK16 interaction. Using a gain-
of-function approach, the i2 loop, i3 loop and carboxy-termi-
nus of the CB2 receptor were systematically replaced with
sequences of the CB1 receptor. We successfully created chi-
meric receptors that showed enhanced ability to activate phos-
pholipase C. The present study describes the construction of a
series of CB1/CB2 chimeras and the characterization of their
ability to couple to GK16.
2. Materials and methods
2.1. Materials
The cDNA clones of the human cannabinoid CB1 receptor, human
cannabinoid CB2 receptor and human GK16 were gifts from Dr. M.
Parmentier (Universite¤ Libre de Bruxelles, Brussels, Belgium), Dr. S.
Munro (Medical Research Council, London, UK) and Dr. M. Simon
(California Institute of Technology, Pasadena, CA, USA), respec-
tively. WIN55,212-2 was purchased from Research Biochemicals (Na-
tick, MA, USA). T7 Sequenase v2.0 sequencing kit, myo-[2-
3H]inositol (115 Ci/mmol) and [125I]cAMP (2000 Ci/mmol) were pur-
chased from Amersham Pharmacia Biotech (Piscataway, NJ, USA).
[3H]CP55,940 (180 Ci/mmol) was purchased from New England Nu-
clear (Boston, MA, USA). Thermostable DNA polymerases and re-
striction enzymes were purchased from New England Biolabs (Bev-
erly, MA, USA). Cell culture reagents were purchased from Gibco
BRL (Grand Island, NY, USA) or Biowhittaker (Walkersville, MD,
USA). All other chemicals were purchased from Sigma Chemical Co.
(St. Louis, MO, USA), Fisher Scienti¢c (Hanover Park, IL, USA) or
as indicated.
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2.2. Construction of wild type and chimeric receptors
All cDNA clones used for transient transfection were inserted in
eukaryotic expression plasmids 3P to the cytomegalovirus promoter.
The cDNA clones of the human cannabinoid CB1 and CB2 receptors
were inserted into pRcCMV (Invitrogen, San Diego, CA, USA) and
human GK16 was obtained as a gift in the vector pCIS.
Chimeras that contain substitutions of the entire cytoplasmic do-
main were generated by polymerase chain reaction (PCR)-based mu-
tagenesis [10] with the high ¢delity thermostable Vent or Vent (exo-)
DNA polymerase using either the cannabinoid CB1 or CB2 receptor
cDNA as the template. The chimeric CB1/CB2 PCR fragments gen-
erated using these two DNA polymerases were mostly blunt-ended
and were subcloned into ScaI-digested pBluescript KS (Stratagene,
La Jolla, CA, USA). Positive clones were transferred into the
pRcCMV-based plasmids containing the cannabinoid receptor
cDNA using appropriate restriction sites. Chimeras with smaller sub-
stitutions were constructed by oligonucleotide-directed mutagenesis
using a Muta-gene M13 in vitro mutagenesis kit (Bio-Rad, Richmond,
CA, USA). Uracil-containing single-stranded template was generated
with the helper phage R408 (Promega, Madison, WI, USA) or
RZ1032 (Quantum Biotechnologies, Laval, QC, Canada). All mutants
were analyzed by restriction analysis and double-stranded dideoxy
sequencing.
2.3. Cell culture and transfection of COS7 cells
Monkey kidney COS7 cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) with 10% fetal calf serum, penicillin G (100
U/ml), streptomycin (100 Wg/ml) and amphotericin B (0.25 Wg/ml) in a
humidi¢ed environment containing 5% CO2 and 95% air at 37‡C.
COS7 cells were transfected according to the method described by
O¡ermanns and Simon [2] and Ho et al. [6] with modi¢cations. Cells
were transfected with the wild type or chimeric cannabinoid receptor
(1.25 Wg) and GK16 (1.25 Wg) using lipofectamine or lipofectamine
2000 (Gibco) in serum-free OPTI-MEM (Gibco). The total amount
of DNA and lipofectamine used was maintained constant among
di¡erent transfection experiments with the vector pRcCMV.
2.4. Determination of inositol phosphate level
The formation of inositol phosphates was measured as described
[2,6]. Brie£y, 20^24 h post-transfection, cells were labeled for 24^28 h
with 1 WCi/ml myo-[2-3H]inositol in inositol-free DMEM (Gibco) and
20% dialyzed fetal calf serum (Gibco). Cells were treated with
WIN55,212-2 prepared in inositol-free DMEM containing 10 mM
LiCl and 1 mg/ml fatty acid-free bovine serum albumin for 20 min
at 37‡C. Total inositol phosphate accumulation (inositol monophos-
phate+inositol bisphosphate+inositol 1,4,5-trisphosphate) was ex-
pressed as percent of basal level determined in vehicle-treated cells
in the absence of the agonist.
2.5. Determination of cAMP level
Adenylyl cyclase activity was assayed by cAMP formation accumu-
lated in whole cells [11]. cAMP levels were measured by radioim-
munoassay using anti-cAMP antibodies (gift from Dr. A.F. Parlow
of the National Hormone and Pituitary Program, Torrance, CA,
USA, lot number CV-27) according to the methods of Richman et
al. [12].
2.6. Radioligand binding assay
Because of the large number of chimeric receptors, the Bmax and Kd
values were calculated from competition instead of saturation binding
assays according to the method described by DeBlasi et al. [13]. The
preparation of membranes and binding assays were performed as
reported previously [6]. Various concentrations of CP55,940 were
used to compete with 0.5 nM [3H]CP55,940 (1 h at 30‡C). Non-spe-
ci¢c binding was determined in the presence of 10 WM (3)-v9-tetra-
hydrocannabinol.
2.7. Data analysis
Data shown in the ¢gures and table are expressed as meanUS.E.M.
GraphPad Prism 3.02 (San Diego, CA, USA) was used to perform
two-way analysis of variance (ANOVA) to test for any concentration-
dependent e¡ect and for the di¡erence between the wild type and
mutant receptors. The Bonferroni post-hoc test was used to test for
di¡erences between the wild type and mutant receptor at each con-
centration of agonist. GraphPad Prism 3.02 was also used to calculate
IC50 values of binding assays. The Bmax and Kd values were calculated
using the following equations: Kd = IC503L and Bmax = (BoUIC50)/L,
where L is the concentration of the radioligand and Bo is the specif-
ically bound radioligand determined in the absence of the competitor
[13].
Table 1
Binding parameters and inositol phosphate (IP) response of wild type (WT) and chimeric cannabinoid receptors
Bmax (pmol/mg protein) Kd (nM) IP response (%)
Wild type
WT CB1 0.34U 0.13 (5) 0.58U 0.11 (6) 161.45U 3.89 (32)
WT CB2 0.40U 0.17 (5) 0.67U 0.15 (5) 103.40U 2.22 (12)
Single mutant
C2 0.45U 0.13 (5) 0.65U 0.12 (4) 104.19U 4.28 (10)þ
C3 0.33U 0.11 (3) 0.85U 0.17 (3) 130.99U 4.60 (11)þ;*
CT 0.32U 0.20 (3) 0.48U 0.26 (4) 116.64U 4.89 (9)þ;*
Double mutant
C2C3 0.37U 0.08 (6) 0.57U 0.13 (7) 160.38U 6.81 (12)*
C2CT 0.36U 0.15 (4) 0.68U 0.21 (4) 133.72U 4.77 (13)þ;*
C3CT 0.37U 0.19 (4) 0.57U 0.13 (4) 124.27U 5.11 (12)þ;*
Triple mutant
C2C3CT 0.40U 0.11 (6) 0.49U 0.08 (6) 160.23U 7.81 (15)*
i3 loop mutant
C3ETM 0.32U 0.10 (3) 0.64U 0.17 (3) 154.58U 6.15 (9)*
C3T 0.44U 0.13 (5) 0.59U 0.16 (7) 147.75U 5.49 (6)*
C3EM 0.56U 0.22 (3) 0.57U 0.17 (3) 144.19U 4.49 (9)*
C3E 0.37U 0.11 (6) 0.54U 0.10 (10) 124.68U 5.67 (12)þ;*
C3M 0.39U 0.10 (4) 0.66U 0.17 (4) 110.43U 4.50 (13)þ
C3A 0.37U 0.15 (3) 0.55U 0.09 (3) 131.23U 9.57 (11)þ;*
C3AM 0.37U 0.17 (3) 0.54U 0.16 (4) 122.40U 4.85 (5)þ;*
C3S 0.49U 0.12 (3) 0.39U 0.12 (3) 120.77U 6.08 (6)þ
COS7 cells were transfected with the indicated cannabinoid receptor and GK16. Two days post-transfection, binding studies or IP accumulation
experiments were performed. The Bmax and Kd values were calculated as described in Section 2. The IP responses represent the percent of basal
level of total IP accumulation in cells stimulated with WIN55,212-2 (10 WM). All results are expressed as meanUS.E.M. The numbers in paren-
theses indicate the numbers of independent transfection experiments performed. The Bmax and Kd values are not signi¢cantly di¡erent between
the chimeras and the wild type CB1 or CB2 receptor.
þP6 0.05, signi¢cantly di¡erent from WT CB1 (Bonferroni post-hoc t-test); *P6 0.05, signi¢cantly di¡erent from WT CB2 (Bonferroni post-
hoc t-test).
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3. Results and discussion
As the ¢rst step toward understanding receptor^GK16 inter-
action, a series of CB1/CB2 chimeras were constructed by
substituting di¡erent cytoplasmic regions of the CB2 receptor
with corresponding sequences of the CB1 receptor. Since the
ability to activate phospholipase C can be a¡ected by the
expression level or binding a⁄nity of the chimeras, their
Bmax and Kd values were determined by [3H]CP55,940 binding
studies and were not signi¢cantly di¡erent from those of the
wild type CB1 or CB2 receptor (Table 1). Therefore, changes
in the level of activation were not due to di¡erences in ex-
pression levels or agonist binding a⁄nity of the chimeras.
Numerous studies on receptor^GK interaction indicate that
sequences in the i2 and i3 loops and the intracellular carboxy-
terminus are responsible for the selectivity and a⁄nity of re-
ceptor-GK coupling (for reviews, see [14,15]). Therefore, single
mutants were constructed with substitution of the i2 loop
(C2), the i3 loop (C3) or the intracellular carboxy-terminus
(CT) (Fig. 1A). Each of the chimeric receptors was co-ex-
pressed with GK16 in COS7 cells (Fig. 2A). As reported pre-
viously [9], WIN55,212-2 resulted in a concentration-depen-
Fig. 1. Amino acid sequences and schematic representations of the CB1, CB2 and the CB1/CB2 chimeric receptors. A: Amino acid sequences of
the CB1 and CB2 receptors and the single mutants C2, C3 and CT. Sequences were aligned with the CLUSTALW program. Conserved amino
acids between the CB1 and CB2 receptors are marked as ‘+’. Gaps introduced for better alignment of the sequences are hyphenated. Putative
transmembrane regions are shaded in light gray. Sequences of the CB1 receptor in the chimeras are shown in white (with dark gray back-
ground). B: Schematics showing the structure of the double mutants C2C3, C2CT, C3CT and the triple mutant C2C3CT. C: Amino acid se-
quences of the i3 loop chimeras. Putative transmembrane regions are shaded in light gray. Sequences of the CB1 receptor in the chimeras are
shown in white. Bar graph (lower right) shows the stimulation of inositol phosphate formation when COS7 cells transfected with cDNAs en-
coding the indicated receptor and GK16 were stimulated with WIN55,212-2 (10 WM). Results were normalized to percent of basal level of total
inositol phosphate accumulation in each experiment and are expressed as meanUS.E.M. Results from cells co-expressing the indicated chimeric
receptor and GK16 are signi¢cantly di¡erent from those co-expressing the CB1 receptor and GK16 (Bonferroni post-hoc t-test, þP6 0.05). Results
from cells co-expressing the indicated chimeric receptor and GK16 are signi¢cantly di¡erent from those co-expressing the CB2 receptor and GK16
(Bonferroni post-hoc t-test, *P6 0.05).
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dent increase in phospholipase C activation in cells expressing
GK16 and the wild type CB1 but not the wild type CB2 recep-
tor. The CB1 receptor did not couple to endogenous or co-
expressed GKq or GK11 in COS7 cells, indicating that the phos-
pholipase C activation was mediated by coupling of the CB1
receptor to the expressed GK16 [6]. In cells co-expressing the
single mutants C3 or CT and GK16, WIN55,212-2 produced
phospholipase C activation greater than those expressing the
CB2 receptor and GK16, but the level was signi¢cantly lower
than that of the CB1 receptor. These results indicate that
substitution of a single cytoplasmic region is not su⁄cient
to enable CB2 receptors to fully activate GK16 like the CB1
receptor.
A second series of mutants (C2C3, C2CT, C3CT, C2C3CT,
Fig. 1B) containing combinations of the cytoplasmic regions
from the CB1 receptor were, therefore, constructed and co-
expressed with GK16. The double mutants C2C3, C2CT and
C3CT still showed signi¢cantly lower levels of phospholipase
C activation than the wild type CB1 receptor (Fig. 2B). How-
ever, the triple mutant C2C3CT showed a similar level of
phospholipase C activation as the CB1 receptor.
These ¢ndings suggest that all three intracellular regions are
required for interacting with GK16. Replacement of only one
or two of these three regions enhanced the ability to activate
phospholipase C but not to the same extent as the triple mu-
tant that had all three regions replaced. Other studies on CB1
receptor^GKi=o interaction indicate that cytoplasmic domains
of the CB1 receptor di¡erentially interact with speci¢c GKi and
GKo subtypes. Using GTPQS binding, anti-peptide antibody
and immunoprecipitation approaches, the amino-terminus of
the i3 loop and the carboxy-terminus of the CB1 receptor were
demonstrated to couple to GKi and adenylyl cyclase inhibi-
tion. In addition, the carboxy-terminus of the CB1 receptor
was shown to associate with GKi3 and GKo, but not with GKi1
or GKi2 [16^18]. Therefore, di¡erent cytoplasmic regions of the
CB1 receptors are involved in interacting with GK16, GKi and
GKo subunits.
Many studies have shown the involvement of the amino-
and carboxy-termini of the i3 loop in G protein coupling
[9,14,15]. Amino acid sequences involved in GKq or GKs acti-
vation have been mapped to di¡erent domains of the i3 loop
of the K1B-adrenergic, M1 muscarinic and V2 vasopressin re-
ceptors [9,14,15,19,20]. Therefore, another goal of this study is
to examine the sub-domains within the i3 loop for coupling
selectivity to GK16. A series of chimeras that have the C2CT
6
Fig. 2. Stimulation of inositol phosphate formation in COS7 cells
co-expressing the wild type or chimeric receptor and GK16. COS7
cells were co-transfected with cDNAs encoding the indicated recep-
tor and GK16 as described in Section 2. After 48 h, [3H]inositol-la-
beled cells were incubated with and without (basal level) the indi-
cated concentrations of WIN55,212-2 for 20 min in duplicates.
Results were normalized to percent of basal level of total inositol
phosphate accumulation in each experiment. Data are expressed as
meanUS.E.M. from at least three independent transfection experi-
ments. Control COS7 cells that were untransfected, vector-trans-
fected or transfected with the receptor alone did not result in signi¢-
cant changes in inositol phosphate accumulation over the same
concentrations of WIN55,212-2 (data not shown). Results from cells
co-expressing the indicated chimeric receptor and GK16 are signi¢-
cantly di¡erent from those co-expressing the CB1 receptor and GK16
(þP6 0.05, ANOVA). Results from cells co-expressing the indicated
chimeric receptor and GK16 are signi¢cantly di¡erent from those co-
expressing the CB2 receptor and GK16 (*P6 0.05, ANOVA).
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backbone, as well as substitutions of the CB1 receptor sequen-
ces into the i3 loop of the CB2 receptor at regions that are
di¡erent between the two receptors were constructed (i3 loop
mutants, Fig. 1C). Two of the mutants with substitutions
toward the carboxyl half of the i3 loop, C3ETM and C3T,
showed phospholipase C activation similar to that of the CB1
receptor and C2C3CT (Figs. 1C and 2C). Phospholipase C
activation mediated by the other i3 loop mutants was still
signi¢cantly di¡erent from the CB1 receptor (Fig. 2D).
These ¢ndings suggested that the substituted amino acids
EDGKV and TRPD toward the carboxy-terminus of the i3
loop of C3ETM and C3T are probably involved in interacting
with GK16 or maintaining a proper conformation for the in-
teraction. In contrast, substitution of sequences towards the
N-terminus of the i3 loops did not confer the same degree of
activation. The length of the i3 loop has also been suggested
to contribute to GK selectivity [19]. However, the length of the
i3 loop in the active mutants C3ETM and C3T is the same as
that of the CB2 receptor, indicating that length is not a con-
tributing factor in this case.
The GK16-coupled domains have also been studied in the
K1B-adrenergic receptor which can couple to GKq=11, GK14
and GK16 [7,9]. Mutagenesis studies of the i3 loop showed
that only deletion of the amino half of the i3 loop, but not
other deletions in the same loop, disrupted GK16 coupling. The
di¡erence between the two receptors may be related to the fact
that the K1B-adrenergic receptor can also interact with GKq=11
but the CB1 receptor cannot [6]. In addition, because the
amino-terminal mutant in their study also disrupted the cou-
pling to GKq=11 and GK14 [9], it was not clear whether this
mutant was functional.
Both the CB1 and CB2 receptors coupled to the inhibition
of adenylyl cyclase [11,21]. To exclude the possibility that the
decrease in phospholipase C activation was due to improper
folding of the intracellular loops, the ability of these mutants
to inhibit adenylyl cyclase was tested as an independent func-
tion (Fig. 3). All mutants examined were able to inhibit ade-
nylyl cyclase to a similar extent as the wild type CB1 or CB2
receptors, indicating that the structure of the chimeras was
not grossly altered. The chimeras maintained the ability to
couple to adenylyl cyclase as an independent e¡ector, prob-
ably through GKi=o.
In summary, a gain-of-function approach was used to suc-
cessfully construct chimeric CB1/CB2 receptors that showed
enhanced ability to activate phospholipase C. Receptor^GK16
interaction depends on the i2 loop, i3 loop and carboxy-
terminus. Speci¢c sub-domains within the i3 loop involved
in coupling were also identi¢ed. Mutagenesis studies of
some G protein-coupled receptors (e.g. muscarinic, L-adrener-
gic and V2 vasopressin receptors) demonstrated that the
N- and/or C-termini of the i3 loop can form K-helices, which
are suggested to be involved in GK coupling. However, no
structural element or sequence requirement can be generalized
for all G protein-coupled receptors [14,15]. Taken together,
our results further support the diversity of mechanisms by
which receptor^GK coupling selectivity can be achieved.
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Fig. 3. Inhibition of forskolin-stimulated cAMP formation in wild
type and chimeric CB1/CB2 receptors. COS7 cells were co-trans-
fected with cDNAs encoding the indicated receptor and GK16 as de-
scribed in Section 2. Two days post-transfection, the cells were
stimulated with forskolin in the absence or presence of a maximal
concentration of WIN55,212-2 (1 WM). Results were normalized to
the percent of forskolin-stimulated cAMP level. Data are expressed
as meanUS.E.M. from at least three independent transfection ex-
periments. The basal and forskolin-stimulated cAMP levels are
9.20U 0.83 and 39.91U 1.91 pmol/mg protein, respectively. Control
cells that were vector-transfected or untransfected did not show any
inhibition of forskolin-stimulated cAMP level.
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